ENZ Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Stats
Объем за сегодня	114 913
Средний объем	109 219
Рыночная капитализация	53.79M
EPS	$0 ( 2024-03-19 )
Дата следующего отчета о доходах	( $0 ) 2024-06-12
Last Dividend	$0.0470 ( 1995-06-29 )
Next Dividend	$0 ( N/A )
P/E	-2.23
ATR14	$0.00300 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Cannon Kara	Buy	150 000	Common Stock
2024-02-21	Cannon Kara	Buy	10 640	Common Stock
2024-02-21	Cannon Kara	Sell	5 823	Common Stock
2024-02-23	Eckert Patricia	Buy	75 000	Stock Option (to acquire shares of Common Stock)
2024-01-31	Pully Steven J	Buy	79 365	Common Stock

INSIDER POWER
88.53
Last 85 transactions
Buy: 4 325 861 \| Sell: 177 248

Объем Корреляция

Длинно: 0.27 (neutral)

Кратко: -0.56 (weak negative)

Signal:(51.331) Neutral

Enzo Biochem Inc Корреляция

10 Самые положительные корреляции
YSAC	0.906
TSQ	0.849
HZN	0.841
DTC	0.828
CRD-A	0.819

10 Самые отрицательные корреляции
FPEI	-0.872
ASB-PE	-0.868
CUBB	-0.868
GL	-0.855
FLR	-0.852
NX	-0.843
MBI	-0.836
PQDI	-0.832
BGSF	-0.832
SPNT-PB	-0.825

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Enzo Biochem Inc Корреляция - Валюта/Сырье

-0.07
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.19
( neutral )

Enzo Biochem Inc Финансовые показатели

Annual	2023
Выручка:	$31.06M
Валовая прибыль:	$11.57M (37.24 %)
EPS:	$-1.270

FY	2023
Выручка:	$31.06M
Валовая прибыль:	$11.57M (37.24 %)
EPS:	$-1.270

FY	2022
Выручка:	$107.07M
Валовая прибыль:	$41.97M (39.20 %)
EPS:	$-0.460

FY	2021
Выручка:	$117.73M
Валовая прибыль:	$53.58M (45.51 %)
EPS:	$0.160

Financial Reports:

No articles found.

Enzo Biochem Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Enzo Biochem Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 5.02 - average (34.50%) | Divividend Growth Potential Score: 0.366 - No dividend growth expected in the near future

Information

First Dividend	$0.0470	1995-06-29
Last Dividend	$0.0470	1995-06-29
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0470	--
Avg. Dividend % Per Year	0.00%	--
Score	0.82	--
Div. Sustainability Score	5.02
Div.Growth Potential Score	0.366
Div. Directional Score	2.69	--

Next Divdend (Est)
(2024-04-28)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.82

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
1995	$0.0470	0.58%
1996	$0	0.00%
1997	$0	0.00%
1998	$0	0.00%
1999	$0	0.00%
2000	$0	0.00%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	2.58	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.333	1.200	10.00	10.00	[0 - 0.3]
returnOnEquityTTM	0.545	1.500	5.06	7.59	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.20	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.78	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.58	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0444	-1.500	9.26	-10.00	[0 - 0.6]
interestCoverageTTM	33.77	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.879	2.00	-0.293	-0.586	[0 - 30]
freeCashFlowPerShareTTM	-0.909	2.00	-0.455	-0.909	[0 - 20]
debtEquityRatioTTM	0.0621	-1.500	9.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	-1.203	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.348	1.000	-8.96	-8.96	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-10.10	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.129	0.800	-2.47	-1.977	[0.5 - 2]
Total Score				5.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	1.605	1.000	9.94	0	[1 - 100]
returnOnEquityTTM	0.545	2.50	6.82	7.59	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.909	2.00	-0.303	-0.909	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.879	2.00	-0.293	-0.586	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.00912	1.500	-3.39	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.47	1.000	-10.00	0	[0.1 - 0.5]
Total Score				0.366

Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.